1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Gram-Positive Bacterial Infections Global Clinical Trials Review, H2, 2014

Gram-Positive Bacterial Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Gram-Positive Bacterial Infections Global Clinical Trials Review, H2, 2014" provides data on the Gram-Positive Bacterial Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gram-Positive Bacterial Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gram-Positive Bacterial Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Gram-Positive Bacterial Infections Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Gram-Positive Bacterial Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Gram-Positive Bacterial Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Gram-Positive Bacterial Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Gram-Positive Bacterial Infections 25
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Gram-Positive Bacterial Infections Therapeutics Clinical Trials 35
Prominent Drugs 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
GlaxoSmithKline plc 37
Clinical Trial Overview of GlaxoSmithKline plc 37
Pfizer Inc. 49
Clinical Trial Overview of Pfizer Inc. 49
Sanofi 55
Clinical Trial Overview of Sanofi 55
Merck and Co., Inc. 62
Clinical Trial Overview of Merck and Co., Inc. 62
Cubist Pharmaceuticals, Inc. 66
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 66
Novartis AG 69
Clinical Trial Overview of Novartis AG 69
Theravance, Inc. 71
Clinical Trial Overview of Theravance, Inc. 71
AstraZeneca PLC 73
Clinical Trial Overview of AstraZeneca PLC 73
Emergent BioSolutions Inc. 75
Clinical Trial Overview of Emergent BioSolutions Inc. 75
Astellas Pharma Inc. 76
Clinical Trial Overview of Astellas Pharma Inc. 76
Clinical Trial Overview of Top Institutes / Government 78
The National Institute of Allergy and Infectious Diseases 78
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 78
University of Oxford 80
Clinical Trial Overview of University of Oxford 80
Health Protection Agency 81
Clinical Trial Overview of Health Protection Agency 81
Assistance Publique - Hopitaux de Paris 82
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 82
John D. Dingell VA Medical Center 83
Clinical Trial Overview of John D. Dingell VA Medical Center 83
University of Pittsburgh 84
Clinical Trial Overview of University of Pittsburgh 84
Uniformed Services University of the Health Sciences 85
Clinical Trial Overview of Uniformed Services University of the Health Sciences 85
Johns Hopkins University 86
Clinical Trial Overview of Johns Hopkins University 86
Duke University 87
Clinical Trial Overview of Duke University 87
Centers for Disease Control and Prevention 88
Clinical Trial Overview of Centers for Disease Control and Prevention 88
Five Key Clinical Profiles 89
Appendix 107
Abbreviations 107
Definitions 107
Research Methodology 108
Secondary Research 108
About GlobalData 109
Contact Us 109
Disclaimer 109
Source 109

List of Tables

Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Gram-Positive Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Gram-Positive Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Gram-Positive Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Gram-Positive Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Gram-Positive Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Gram-Positive Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Gram-Positive Bacterial Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Gram-Positive Bacterial Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gram-Positive Bacterial Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 32
Gram-Positive Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 33
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 34
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 37
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 49
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 55
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 62
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 66
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 69
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Theravance, Inc., 2014* 71
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 73
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Emergent BioSolutions Inc., 2014* 75
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 76
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 78
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014* 80
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Health Protection Agency, 2014* 81
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 82
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by John D. Dingell VA Medical Center, 2014* 83
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 84
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Uniformed Services University of the Health Sciences, 2014* 85
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014* 86
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 87
Gram-Positive Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 88

List of Figures

Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Gram-Positive Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Gram-Positive Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Gram-Positive Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Gram-Positive Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Gram-Positive Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Gram-Positive Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Gram-Positive Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 32
Gram-Positive Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 33
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 34
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Gram-Positive Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the ...

Global Feed Antibiotics Market

December 2016 $ 4250

Acetic Acid Markets In China

January 2017 $ 4000

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.